Clinical Trials Market

Clinical Trials Market (Phase: Phase I, Phase II, Phase III, and Phase IV; Study Design: Interventional Trials, Observational Trials, and Expanded Access Trials; and Indication: Autoimmune/Inflammation, Pain Management, Cardiovascular, CNS Condition, Oncology, Diabetes, Obesity, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Success of Clinical Trials for COVID-19 Vaccines Boosts Market Growth

The coronavirus pandemic has brought research labs and healthcare institutions under great scrutiny for accelerating the clinical trials for COVID-19 vaccines. As such, the success in these clinical trials has led to global recognition of India for supplying several lack of free doses to Brazil, Bangladesh, Algeria, and South Africa. Countries such as Sri Lanka are following suit whilst creating incremental opportunities for stakeholders in the clinical trials market.

The Food & Drug Administration (FDA) is creating awareness about Coronavirus Treatment Acceleration Program (CTAP) in order to bring economies to normal. Companies in the clinical trials market are taking advantage of this program to make new treatments available to patients as quickly as possible.

clinical trials market segmentation

To know the scope of our report Get a Sample on Clinical Trials Market

Clinical Trial Recruitment Companies Essential for Matching Patients with Right Trial

The clinical trials market is estimated to cross US$ 83.5 Bn by the end of 2030. However, finding the right patients is one of the most important pieces of the puzzle with respect to conducting clinical trials. Hence, stakeholders are working with experts at clinical trial recruitment companies to match patients with the right trials.

Slow recruitment is another challenge faced by companies in the market. Hence, companies are becoming aware about scrutinizing existing patient data to anticipate potential recruitment challenges in the long run. Clinical trial innovations are anticipated to bolster participation from volunteers.

Get a glimpse of the in-depth analysis through our Report Brochure

FDA Guidelines Pave Way for Innovations for At-home, At-clinic Clinical Trials

Companies in the market are following guidelines of the FDA to advance in processes. They are referring to FDA guidance about Severely Debilitating or Life-Threatening Hematologic Disorders (SDLTHDs) in patients. Companies are increasing efforts to fill in the gap between scientific and technical complexities of clinical trials. Thus, companies are investing in improving the academia and are developing new incentives that reward collaboration from volunteers.

Companies in the market are taking additional efforts to develop networks that enable procedures at a patient’s home or at their private doctor’s clinic. This has led to innovations in sensor devices, patient reported outcomes on their computers, and flash pictures of their lesions from their cellphones that contribute toward processes.

Coronavirus Pandemic Pushes Sponsors, Patients to Adopt Virtual Clinical Trials

Compliance with protocols is one of the key trends followed by stakeholders in the clinical trials market. Clinical trials supervised by Principal Investigators are gaining prominence in the market landscape. Continued positive cases for coronavirus have increased relevancy and role of stakeholders in the market. This shift has pushed clinical trials to go virtual.

Stakeholders in the market are teaming up with virtual clinical trial experts to capitalize on business opportunities during the ongoing pandemic. Even regulatory authorities have released guidelines to assist sponsors and patients via telemedicine and virtual trial tools to create viable solutions for current operational problems.

Digital Health Innovations Give Impetus to IoMT for Enhancing Clinical Development Programs

The proliferation of digital innovations with the help of wearables and sensors is translating into value grab opportunities for companies in the clinical trials market. ICON plc— a clinical research organization company is researching how digital endpoints, including digital biomarkers can improve trial outcomes. This has led to the adoption of digital health technologies that enable appropriate device selection and data strategies.

Digital health innovations hold promising potentials to better manage chronic diseases and improve patient access to healthcare services. Stakeholders and sponsors are taking efforts to improve adherence to medications and prevent its complications in patients. The Internet of Medical Things (IoMT) has the potential to enhance clinical development programs involving med-tech and pharmaceutical companies.

clinical trials market infographic

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

There is a need for trial innovations since recently several volunteers were given wrong dose of the late stage clinical trial of the Oxford/AstraZeneca Covid-19 vaccine.

The clinical trials market is predicted to advance at a modest CAGR of 5.4% during the forecast period. This is evident since stakeholders need to address challenges pertaining to site management and compliance in order to improve trial outcomes. Hence, companies are developing clinical trial timelines to avoid delays, and are increasing transparency with their sponsors to offer them a 360 degree view of the processes happening at development centers. IoMT is acting as a key driver for the market.

Clinical Trials Market: Overview

  • According to Transparency Market Research’s latest report on the global market for the historical period 2018–2019 and forecast period 2020–2030, high prevalence and increase in incidence rate of chronic diseases and rise in R&D activities in biotechnology & pharmaceuticals industries are projected to drive the global market during the forecast period
  • According to the report, the global market was valued over US$ 46.7 Bn in 2019 and is anticipated to expand at a CAGR of 5.4% from 2020 to 2030

High Prevalence and Increase in Incidence Rate of Chronic Diseases to Drive Demand for Clinical Trials: Key Drivers

  • Chronic diseases such as chronic respiratory diseases (CRD), diabetes, chronic kidney diseases (CKD), cancer, cardiac stroke, and neurological disorders are the leading causes of disability and mortality across the globe
  • The emergence and outbreak of various infectious and chronic diseases have created challenges and new opportunities for researchers to develop new diagnostic tools, tests, drugs, and vaccines for early diagnosis, prevention, and cure of such diseases
  • Hepatitis and HIV are the other major infectious diseases. According to the World Health Organization (WHO), as of October 2017, around 71 million people across the world were estimated to have hepatitis C infection. The WHO also stated that 36.7 million people were affected with HIV across the globe.
  • An article published by Columbia, Mailman School of Public Health on infectious disease epidemiology stated that infectious diseases continue to have a substantial impact on the health of communities across the world. Various seasonal outbreaks of diseases in certain parts of the world, global epidemics, the threat of resistant bacteria, and the challenge of emerging and newly identified pathogens increase the need of new methods to detect such pathogens, to understand their pathogenesis, and to devise effective interventions for their prevention and control.
  • These factors have led to an increase in demand for clinical trials, and are expected to drive the market for clinical trials from 2020 to 2030

Rise in R&D Activities in Biotechnology and Pharmaceuticals Industries Boosts Market Growth

  • Clinical research organizations, diagnostic laboratories, and biotechnology players are engaged in the development of newer diagnostic tests to address the unmet needs in the healthcare industry. The life science industry’s R&D spending is driven primarily by the mass and research intensity of the biopharmaceutical sector, which accounts for nearly 85% of all expenditure.
  • Additionally, laboratories strive to improve equipment cost and performance. UHPLC and ultra-fast mass spectrometers are more reliable, faster, and more sensitive as a result of research initiatives by major players.
  • Acceleration in biopharmaceutical R&D innovation, buoyed by several contributing factors such as precision medicine getting into gear in rare diseases, cancer, and autoimmune diseases; immunotherapy, expansion of therapeutic modalities exploiting natural and synthetic biology innovation, and expedited regulatory pathways boost the growth of the clinical trials market

Patient Recruitment and Retention to Hamper Global Market

  • Shift in focus toward genetic and rare diseases has made recruitment of relevant patient population a challenging task. Moreover, lack of awareness among patients of clinical trials presents a challenging environment for CROs.
  • Lack of appropriate patient recruitment could have an impact on the scientific and financial viability. According to the Tufts Center for the Study of Drug Development, in 2013, 11% of the sites failed to recruit even a single patient for clinical trial.
  • Other factors responsible for poor patient recruitment are patient’s fear of side effects, illiteracy, language barrier for region-specific clinical trials, and recording of the consent process
  • Factors affecting the retention of patients for clinical trials include serious adverse events, fear of complex medical procedures, poor compliance of protocol, lack of dedication toward patient safety, and lack of support from family. This significantly affects the advancement of clinical trial process and product development.

Clinical Trials Market: Competition Landscape

  • This report profiles major players in the global clinical trials industry based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • Leading players operating in the global market are
    • Laboratory Corporation of America Holdings
    • IQVIA, Inc.
    • Syneos Health
    • Parexel International Corporation
    • PRA Health Sciences, Inc.
    • PPD, Inc.
    • Icon plc
    • Charles River Laboratories, Inc.
    • WuXi AppTec
    • Medpace Holdings, Inc.

Key Developments

  • Key players in the global clinical trials market are engaged in regulatory approvals, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global market. Few expansion strategies adopted by players operating in the global clinical trials business are:
    • In February 2020, Charles River Laboratories International, Inc. signed an agreement to acquire Citoxlab for US$ 510 Mn. Citoxlab is a non-clinical CRO specialized in regulated safety assessment services, non-regulated discovery services, and medical device testing.
    • In November 2019, PPD, Inc. launched site coach where doctors and healthcare centers will receive clinical research at new sites, which will provide sufficient training for physicians and other academic institutions through online for the new clinical researchers
    • In October 2019, Icon plc acquired Symphony Clinical Research to enhance the ability in offering customers hybrid trial solutions and site support services. This acquisition affected the clinical trials directly and improved the services in the research centers.
    • In June 2019, Laboratory Corporation’s Covance Drug Development segment completed the acquisition of Envigo’s nonclinical contract research services business. This acquisition enabled the company to increase its global nonclinical drug development capabilities. As part of this move, Envigo acquired Covance’s research models & services business, leading to the establishment of an organization dedicated to offering a complete range of research models.
    • In October 2018, Parexel International Corporation announced that it would launch new wearable, mobile tech for clinical trials, which will expand the services in clinical research. Microsoft's Azure App Services is one of the mobile tech services, which alerts a healthcare team when there is a patient safety threat.
    • In February 2018, PPD, Inc. and Acurian introduced an innovative clinical trial patient concierge service that provides personalized patient support and improves customer retention. PPD’s Site Coach Service addresses this by providing specialized clinical research education, coaching, and support to new clinical research physicians, hospitals, and academic institutions.
    • In April 2018, ICON plc, a global biopharmaceutical company, announced that it recently agreed with the Intel Pharma Analytics platform in clinical trials, which will help to reduce costs in clinical trials and delivers an excellent patient experience
    • In August 2017, LabCorp, a leading company in life sciences, acquired Chiltren for around US$ 1.2 Bn. The company enhanced end-to-end drug development services and engaged patient care more effectively in the next few years.
    • In May 2017, WuXi AppTec Co., Ltd. announced completion of the acquisition of HD Biosciences (HDB), a leading biology-focused preclinical drug discovery contract research organization (CRO). The acquisition would further strengthen WuXi’s R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi’s open-access enabling service platform.
    • In June 2016, IQVIA, the most significant research organization, launched a continuous glucose monitoring device, which is helpful to record a person's glucose levels throughout the day. Medical device CGM is combined with the consumer wearable devices to record the readings.
    • In June 2015, IQVIA and PRA Health Sciences, two leading companies in pharmaceuticals, announced that with new predictive and advanced analytics technology they plan to improve the performance in clinical trials and improve safety issues
    • In October 2014, Laboratory Corporation of America Holdings acquired Covance, Inc. for US$ 5.6 Bn and became world’s leading health care diagnostic company and leading end-to-end solutions provider for drug development and commercialization
  • The report on the global clinical trials market discussed individual strategies, followed by company profiles of service providers of clinical trials. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global market.

Clinical Trials Market – Segmentation

Phase
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
Study Design
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
Indication
  • Autoimmune/Inflammation
  • Pain Management
  • Cardiovascular
  • CNS Condition
  • Oncology
  • Diabetes
  • Obesity
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of clinical trials market?

It is projected to reach a value of US$ 83.5 Bn by the end of 2030

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 5% from 2020 to 2030.

Which region will account for major share?

North America is expected to account for leading share during the forecast period.

What are the key driving factors for the growth of the clinical trials market?

High prevalence and increase in incidence rate of chronic diseases, and rise in R&D activities in biotechnology & pharmaceuticals industries are anticipated to drive the global market.

Who are the prominent players in the sector?

Laboratory Corporation of America Holdings, IQVIA, Inc., Syneos Health, Parexel International Corporation, PRA Health Sciences, Inc., PPD, Inc., Icon plc, Charles River Laboratories, Inc., WuXi AppTec, and Medpace Holdings, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Clinical Trials Market

    4. Market Overview

        4.1. Introduction

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Clinical Trials Market Analysis and Forecast, 2018–2030

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Number of Clinical Trials

        5.2. Key Industry Events

        5.3. COVID-19 Pandemic Impact on Industry

    6. Global Clinical Trials Market Analysis and Forecast, by Phase 

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Phase, 2018–2030

            6.3.1. Phase I

            6.3.2. Phase II

            6.3.3. Phase III

            6.3.4. Phase IV

        6.4. Market Attractiveness Analysis, by Phase 

    7. Global Clinical Trials Market Analysis and Forecast, by Study Design 

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Study Design, 2018–2030

            7.3.1. Interventional Trials

            7.3.2. Observational Trials

            7.3.3. Expanded Access Trials

        7.4. Market Attractiveness Analysis, by Study Design 

    8. Global Clinical Trials Market Analysis and Forecast, by Indication 

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Indication, 2018–2030

            8.3.1. Autoimmune/Inflammation

            8.3.2. Pain Management

            8.3.3. Cardiovascular

            8.3.4. CNS Condition

            8.3.5. Oncology

            8.3.6. Diabetes

            8.3.7. Obesity

            8.3.8. Others

        8.4. Market Attractiveness Analysis, by Indication 

    9. Global Clinical Trials Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America 

            9.2.2. Europe 

            9.2.3. Asia Pacific

            9.2.4. Latin America 

            9.2.5. Middle East & Africa 

        9.3. Market Attractiveness Analysis, by Country/Region

    10. North America Clinical Trials Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Phase, 2018–2030

            10.2.1. Phase I

            10.2.2. Phase II

            10.2.3. Phase III

            10.2.4. Phase IV

        10.3. Market Value Forecast, by Study Design, 2018–2030

            10.3.1. Interventional Trials

            10.3.2. Observational Trials

            10.3.3. Expanded Access Trials

        10.4. Market Value Forecast, by Indication, 2018–2030

            10.4.1. Autoimmune/Inflammation

            10.4.2. Pain Management

            10.4.3. Cardiovascular

            10.4.4. CNS Condition

            10.4.5. Oncology

            10.4.6. Diabetes

            10.4.7. Obesity

            10.4.8. Others

        10.5. Market Value Forecast, by Country, 2018–2030

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis 

            10.6.1. By Phase 

            10.6.2. By Study Design 

            10.6.3. By Indication 

            10.6.4. By Country

    11. Europe Clinical Trials Market Analysis and Forecast

        11.1.Introduction

            11.1.1. Key Findings

        11.2.Market Value Forecast, by Phase, 2018–2030

            11.2.1. Phase I

            11.2.2. Phase II

            11.2.3. Phase III

            11.2.4. Phase IV

        11.3.Market Value Forecast, by Study Design, 2018–2030

            11.3.1. Interventional Trials

            11.3.2. Observational Trials

            11.3.3. Expanded Access Trials

        11.4.Market Value Forecast, by Indication, 2018–2030

            11.4.1. Autoimmune/Inflammation

            11.4.2. Pain Management

            11.4.3. Cardiovascular

            11.4.4. CNS Condition

            11.4.5. Oncology

            11.4.6. Diabetes

            11.4.7. Obesity

            11.4.8. Others

        11.5.Market Value Forecast, by Country/Sub-region, 2018–2030

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6.Market Attractiveness Analysis 

            11.6.1. By Phase 

            11.6.2. By Study Design 

            11.6.3. By Indication 

            11.6.4. By Country/Sub-region

    12. Asia Pacific Clinical Trials Market Analysis and Forecast

        12.1.Introduction

            12.1.1. Key Findings

        12.2.Market Value Forecast, by Phase, 2018–2030

            12.2.1. Phase I

            12.2.2. Phase II

            12.2.3. Phase III

            12.2.4. Phase IV

        12.3.Market Value Forecast, by Study Design, 2018–2030

            12.3.1. Interventional Trials

            12.3.2. Observational Trials

            12.3.3. Expanded Access Trials

        12.4.Market Value Forecast, by Indication, 2018–2030

            12.4.1. Autoimmune/Inflammation

            12.4.2. Pain Management

            12.4.3. Cardiovascular

            12.4.4. CNS Condition

            12.4.5. Oncology

            12.4.6. Diabetes

            12.4.7. Obesity

            12.4.8. Others

        12.5.Market Value Forecast, by Country/Sub-region, 2018–2030

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6.Market Attractiveness Analysis 

            12.6.1. By Phase 

            12.6.2. By Study Design 

            12.6.3. By Indication 

            12.6.4. By Country/Sub-region

    13. Latin America Clinical Trials Market Analysis and Forecast

        13.1.Introduction

            13.1.1. Key Findings

        13.2.Market Value Forecast, by Phase, 2018–2030

            13.2.1. Phase I

            13.2.2. Phase II

            13.2.3. Phase III

            13.2.4. Phase IV

        13.3.Market Value Forecast, by Study Design, 2018–2030

            13.3.1. Interventional Trials

            13.3.2. Observational Trials

            13.3.3. Expanded Access Trials

        13.4.Market Value Forecast, by Indication, 2018–2030

            13.4.1. Autoimmune/Inflammation

            13.4.2. Pain Management

            13.4.3. Cardiovascular

            13.4.4. CNS Condition

            13.4.5. Oncology

            13.4.6. Diabetes

            13.4.7. Obesity

            13.4.8. Others

        13.5.Market Value Forecast, by Country/Sub-region, 2018–2030

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6.Market Attractiveness Analysis 

            13.6.1. By Phase 

            13.6.2. By Study Design 

            13.6.3. By Indication 

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Clinical Trials Market Analysis and Forecast

        14.1.Introduction

            14.1.1. Key Findings

        14.2.Market Value Forecast, by Phase, 2018–2030

            14.2.1. Phase I

            14.2.2. Phase II

            14.2.3. Phase III

            14.2.4. Phase IV

        14.3.Market Value Forecast, by Study Design, 2018–2030

            14.3.1. Interventional Trials

            14.3.2. Observational Trials

            14.3.3. Expanded Access Trials

        14.4.Market Value Forecast, by Indication, 2018–2030

            14.4.1. Autoimmune/Inflammation

            14.4.2. Pain Management

            14.4.3. Cardiovascular

            14.4.4. CNS Condition

            14.4.5. Oncology

            14.4.6. Diabetes

            14.4.7. Obesity

            14.4.8. Others

        14.5.Market Value Forecast, by Country/Sub-region, 2018–2030

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6.Market Attractiveness Analysis 

            14.6.1. By Phase 

            14.6.2. By Study Design 

            14.6.3. By Indication 

            14.6.4. By Country/Sub-region

    15. Competitive Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2019

        15.3. Company Profiles

            15.3.1. Laboratory Corporation of America Holdings

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Financial Overview

                15.3.1.3. Product Portfolio

                15.3.1.4. Strategic Overview

                15.3.1.5. SWOT Analysis

            15.3.2. IQVIA Inc.

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Financial Overview

                15.3.2.3. Product Portfolio

                15.3.2.4. Strategic Overview

                15.3.2.5. SWOT Analysis

            15.3.3. Syneos Health

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Financial Overview

                15.3.3.3. Product Portfolio

                15.3.3.4. Strategic Overview

                15.3.3.5. SWOT Analysis

            15.3.4. Parexel International Corporation 

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Financial Overview

                15.3.4.3. Product Portfolio

                15.3.4.4. Strategic Overview

                15.3.4.5. SWOT Analysis

            15.3.5. PPD Inc.

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Financial Overview

                15.3.5.3. Product Portfolio

                15.3.5.4. Strategic Overview

                15.3.5.5. SWOT Analysis

            15.3.6. Icon plc

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Financial Overview

                15.3.6.3. Product Portfolio

                15.3.6.4. Strategic Overview

                15.3.6.5. SWOT Analysis

            15.3.7. Charles River Laboratories, Inc.

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Financial Overview

                15.3.7.3. Product Portfolio

                15.3.7.4. Strategic Overview

                15.3.3.5. SWOT Analysis

            15.3.8. WuXi AppTec

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Financial Overview

                15.3.8.3. Product Portfolio

                15.3.8.4. Strategic Overview

                15.3.8.5. SWOT Analysis

            15.3.9. Medpace Holdings, Inc.

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Financial Overview

                15.3.9.3. Product Portfolio

                15.3.9.4. Strategic Overview

                15.3.9.5. SWOT Analysis

    List of Tables

    Table 01: Global Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

    Table 02: Global Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030

    Table 03: Global Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 04: Global Clinical Trials Market Value (US$ Mn) Forecast, by Region, 2018–2030

    Table 05: North America Clinical Trials Market Value (US$ Mn) Forecast, by Country, 2018–2030

    Table 06: North America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

    Table 07: North America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

    Table 08: North America Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 09: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 10: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

    Table 11: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030

    Table 12: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 13: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 14: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

    Table 15: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030

    Table 16: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 17: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 18: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

    Table 19: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030

    Table 20: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 21: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 22: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

    Table 23: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030

    Table 24: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    List of Figures

    Figure 01: Global Clinical Trials Market Value (US$ Mn) Forecast, 2018–2030

    Figure 02: Global Clinical Trials Market Value Share, by Phase, 2019

    Figure 03: Global Clinical Trials Market Value Share, by Indication, 2019

    Figure 04: Global Clinical Trials Market Value Share, by Study Design, 2019

    Figure 05: Global Clinical Trials Market Value Share, by Region, 2019

    Figure 06: Global Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

    Figure 07: Global Clinical Trials Market Value (US$ Mn), by Phase I, 2018–2030

    Figure 08: Global Clinical Trials Market Value (US$ Mn), by Phase II, 2018–2030

    Figure 09: Global Clinical Trials Market Value (US$ Mn), by Phase III, 2018–2030

    Figure 10: Global Clinical Trials Market Value (US$ Mn), by Phase IV, 2018–2030

    Figure 11: Global Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

    Figure 12: Global Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

    Figure 13: Global Clinical Trials Market Value (US$ Mn), Interventional Trials, 2018–2030

    Figure 14: Global Clinical Trials Market Value (US$ Mn), Observational Trials, 2018–2030

    Figure 15: Global Clinical Trials Market Value (US$ Mn), Expanded Access Trials, 2018–2030

    Figure 16: Global Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

    Figure 17: Global Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 18: Global Clinical Trials Market Value (US$ Mn), Autoimmune /Inflammation, 2018–2030

    Figure 19: Global Clinical Trials Market Value (US$ Mn), Pain Management, 2018–2030

    Figure 20: Global Clinical Trials Market Value (US$ Mn), Cardiovascular, 2018–2030

    Figure 21: Global Clinical Trials Market Value (US$ Mn), CNS Condition, 2018–2030

    Figure 22: Global Clinical Trials Market Value (US$ Mn), Oncology, 2018–2030

    Figure 23: Global Clinical Trials Market Value (US$ Mn), Diabetes, 2018–2030

    Figure 24: Global Clinical Trials Market Value (US$ Mn), Obesity, 2018–2030

    Figure 25: Global Clinical Trials Market Value (US$ Mn), Others, 2018–2030

    Figure 26: Global Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 27: Global Clinical Trials Market Value Share Analysis, by Region, 2019 and 2030

    Figure 28: Global Clinical Trials Market Attractiveness Analysis, by Region, 2020–2030

    Figure 29: North America Clinical Trials Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 30: North America Clinical Trials Market Value Share (%), by Country, 2019 and 2030

    Figure 31: North America Clinical Trials Market Attractiveness, by Country, 2020–2030

    Figure 32: North America Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

    Figure 33: North America Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

    Figure 34: North America Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

    Figure 35: North America Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

    Figure 36: North America Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 37: North America Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 38: Europe Clinical Trials Market Value (US$ Mn) Forecast, 2018–2030

    Figure 39: Europe Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 40: Europe Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 41: Europe Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

    Figure 42: Europe Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

    Figure 43: Europe Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

    Figure 44: Europe Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

    Figure 45: Europe Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 46: Europe Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 47: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, 2018–2030

    Figure 48: Asia Pacific Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 49: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 50: Asia Pacific Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

    Figure 51: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

    Figure 52: Asia Pacific Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

    Figure 53: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

    Figure 54: Asia Pacific Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 55: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 56: Latin America Clinical Trials Market Value (US$ Mn) Forecast, 2018–2030

    Figure 57: Latin America Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 58: Latin America Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 59: Latin America Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

    Figure 60: Latin America Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

    Figure 61: Latin America Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

    Figure 62: Latin America Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

    Figure 63: Latin America Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 64: Latin America Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 65: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, 2018–2030

    Figure 66: Middle East & Africa Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 67: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 68: Middle East & Africa Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

    Figure 69: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

    Figure 70: Middle East & Africa Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

    Figure 71: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

    Figure 72: Middle East & Africa Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 73: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 74: Global Clinical Trials Market Share Analysis, by Company, 2019

Copyright © Transparency Market Research, Inc. All Rights reserved